(Q85774777)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25311350%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

title

Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25311350%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

Steven A Rosenberg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25311350%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

14 October 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25311350%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

21 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25311350%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25311350%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25311350%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

630-632

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25311350%20AND%20SRC:MED&resulttype=core&format=json

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.174

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.174

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.174

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.174

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.174

Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.174

Cancer regression in patients after transfer of genetically engineered lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.174

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.174

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.174

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.174

10.1038/NRCLINONC.2014.174

31 March 2020

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25311350%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25311350%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference